Lumvoa received FDA approval as the first TED therapy with data for both active and chronic patients, offering rapid, durable symptom relief in a short 12-week course. The launch targets a $2B market with strong prescriber engagement, broad payer coverage expected in 6–9 months, and a robust patient support program.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.